Intercytex appoints chief financial officer

REGENERATIVE medicine developer Intercytex has appointed Max Herrman as chief financial officer.

Mr Herrman joins from the university IP commercialisation company, Fusion IP, where he held an independent consulting role for the past 12 months.

Prior to this, he spent more than 10 years as a sell-side equity analyst, most recently as managing director and head of European pharmaceutical and biotechnology research at ING equity markets.

Nick Higgins, chief executive officer of Manchester-based Intercytex, said: “We are delighted to welcome Max to the Intercytex team. His strong financial background and experience in the City combined with his deep scientific understanding of our sector brings a wealth of knowledge and expertise to Intercytex, and I am certain that he will make a major contribution to the company’s future growth and development.”